Crossmark

InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

Crossref DOI link: https://doi.org/10.1007/s13300-020-00781-6

Published Online: 2020-02-25

Published Print: 2020-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Battelino, Tadej

Bosnyak, Zsolt

Danne, Thomas

Mukherjee, Bhaswati

Edelman, Steve

Pilorget, Valerie

Choudhary, Pratik

Renard, Eric

Bergenstal, Richard
Funding

Funding for this research was provided by:

Sanofi, Paris, France (NCT04075513)
More Information

Article History

Received: 6 December 2019

First Online: 25 February 2020

Change Date: 18 November 2021

Change Type: Update

Change Details: A peer-reviewed video abstract was retrospectively added to this publication

Change Date: 2 May 2020

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13300-020-00820-2

Change Date: 23 June 2020

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13300-020-00853-7

Updates are available Correction dated 2020-06-23

Click to view Correction: https://doi.org/10.1007/s13300-020-00853-7

Updates are available Correction dated 2020-05-02

Click to view Correction: https://doi.org/10.1007/s13300-020-00820-2